Therapeutic non-invasive brain stimulation in amyotrophic lateral sclerosis: rationale, methods and experience

Edmond, Evan C; Stagg, Charlotte J.; Turner, Martin R

doi:10.1136/jnnp-2018-320213

Cited by 8 publications

(6 citation statements)

References 87 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RTMS was tested in several small studies [2], demonstrating a slight reduction of ALS progression related to duration and frequency of treatment. The main limitations of rTMS are that its after-effects are short-lived and that it can be performed only in specialized centers.…”

mentioning

confidence: 99%

Transcranial static magnetic field stimulation can modify disease progression in amyotrophic lateral sclerosis

et al. 2021

View full text Add to dashboard Cite

mentioning

confidence: 99%

Transcranial static magnetic field stimulation can modify disease progression in amyotrophic lateral sclerosis

et al. 2021

View full text Add to dashboard Cite

“…Another approach for ALS treatment is using non-invasive brain stimulation (NIBS) techniques, which regulate brain activity by means of different energy forms, such as electrical current, magnetic pulses or focused ultrasound given throughout the scalp and skull. Some studies about the employment of NIBS to ALS were reviewed, and these techniques could prove beneficial for ALS after the standardization of stimulation procedures [ 45 ].…”

Section: Introductionmentioning

confidence: 99%

Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis

Sever

Çi̇ftçi̇

DeMi̇rci̇

et al. 2022

IJMS

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a rapidly debilitating fatal neurodegenerative disorder, causing muscle atrophy and weakness, which leads to paralysis and eventual death. ALS has a multifaceted nature affected by many pathological mechanisms, including oxidative stress (also via protein aggregation), mitochondrial dysfunction, glutamate-induced excitotoxicity, apoptosis, neuroinflammation, axonal degeneration, skeletal muscle deterioration and viruses. This complexity is a major obstacle in defeating ALS. At present, riluzole and edaravone are the only drugs that have passed clinical trials for the treatment of ALS, notwithstanding that they showed modest benefits in a limited population of ALS. A dextromethorphan hydrobromide and quinidine sulfate combination was also approved to treat pseudobulbar affect (PBA) in the course of ALS. Globally, there is a struggle to prevent or alleviate the symptoms of this neurodegenerative disease, including implementation of antisense oligonucleotides (ASOs), induced pluripotent stem cells (iPSCs), CRISPR-9/Cas technique, non-invasive brain stimulation (NIBS) or ALS-on-a-chip technology. Additionally, researchers have synthesized and screened new compounds to be effective in ALS beyond the drug repurposing strategy. Despite all these efforts, ALS treatment is largely limited to palliative care, and there is a strong need for new therapeutics to be developed. This review focuses on and discusses which therapeutic strategies have been followed so far and what can be done in the future for the treatment of ALS.

show abstract

“…Increased cortical excitability, thought to reflect pathological changes in the balance of local excitatory and inhibitory neuronal influences that are commonly seen in patients presenting ALS and non-invasive brain stimulation (NIBS), has been shown to modulate cortical activity, with some protocols showing effects that outlast the stimulation by months. Therefore, NIBS has been proposed as a probable candidate to approach therapeutically these disorders associated with pathological neurophysiology activity, such as ALS, among others [15].…”

Section: Introductionmentioning

confidence: 99%

“…Another therapeutic modality to treat ALS is the noninvasive brain stimulation (NIBS), which has been shown to modulate cortical activity, with some protocols leading effects that outlast the stimulation by months. NIBS have been suggested as a potential treatment choice in those processes with associated changes in the cortical neurophysiology [15].…”

Section: Introductionmentioning

confidence: 99%

Introduction to Novel Motor Neuron Disease

Sibat¹,

Valdés²

2020

Novel Aspects on Motor Neuron Disease

View full text Add to dashboard Cite

Motor neuron disease (MND) is a progressive and fatal neuromuscular disease; the most common and severe form of MND presentation is amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease. The majority of ALS patients die within 2-5 years of receiving a diagnosis. Familial ALS is a hereditary form of the disease and accounts for 5-10% of cases, whereas the remaining cases have no clearly defined etiology. ALS affects persons of all ethnicities and races; currently, no curative treatment for ALS is available worldwide. ALS is also the major adult-onset MND and is clinically, pathologically, and genetically associated with fronto-temporal dementia in some cases, which is the second cause of dementia in elderly people. However, MND does not affect sphincter, sexual function, or eye movements. MND is the most common degenerative disorder affecting the upper and lower motor neurons at the same time. Most of the patients presenting MND in our series complained of muscle weakness, muscle wasting, fasciculation, and spasticity plus lower cranial nerve disturbances. According to our bibliographic studies, apart from nusinersen, it seems to be that riluzole and edaravone also improve motor neuron function by acting on SK channels.

show abstract

Therapeutic non-invasive brain stimulation in amyotrophic lateral sclerosis: rationale, methods and experience

Cited by 8 publications

References 87 publications

Transcranial static magnetic field stimulation can modify disease progression in amyotrophic lateral sclerosis

Transcranial static magnetic field stimulation can modify disease progression in amyotrophic lateral sclerosis

Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis

Introduction to Novel Motor Neuron Disease

Contact Info

Product

Resources

About